RxSight withdraws full-year financial guidance while projecting $30M-$40M in revenue from its Alcon partnership in 2026.
RxSight announced it expects $30M to $40M in revenue from its collaboration with Alcon in 2026. The company cited strategic adjustments as the reason for withdrawing its full-year financial guidance during its Q2 2026 earnings call.
Management previously provided annual forecasts but opted to pause guidance without specifying a timeline for reinstatement. The Alcon revenue projection remains a key financial highlight amid the broader guidance withdrawal.
No immediate market reaction was disclosed in the earnings discussion.